Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein
Keyword(s):
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8+T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.
2019 ◽
Vol 220
(10)
◽
pp. 1558-1567
◽
2020 ◽
Vol 20
(7)
◽
pp. 827-838
◽
2015 ◽
Vol 4
(4)
◽
pp. 491-501
◽
2018 ◽
Vol 66
(2)
◽
pp. 831-841
◽
Keyword(s):
2004 ◽
Vol 11
(2)
◽
pp. 406-410
◽